Leveraging biomarkers to develop innovative antibody-drug conjugates for the treatment of advanced solid tumors

In an interview with Pharm Exec Editor-in-Chief Don Tracy, Pedro Valencia, vice president of solid tumor pipeline strategy and execution at AbbVie, talks about using novel cancer biomarkers to develop first-in-class antibody-drug conjugates (ADCs) in the future and the possibilities this could bring.